
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Letters to the Editor |
Division of Medical Oncology, Hospital Universitario, 12 de Octubre, 28041 Madrid, Spain, and 3Division of Pathology, CSUB, 08907 Barcelona, Spain
In September 1998, we published in Clinical Cancer Research a study examining the clinical value of angiogenin, a protein implicated in angiogenesis (1) . Our article described the analysis of breast carcinoma specimens for the expression of angiogenin. We showed that angiogenin expression was elevated in a majority of breast carcinoma extracts and that the expression of tumor angiogenin, but not of circulating angiogenin, was an independent prognostic indicator of favorable outcome in patients with operable breast cancer (2) . Recently, Shimoyama et al. (3) have reported that serum angiogenin concentration is elevated in colorectal patients and that the degree of its elevation correlates with the degree of cancer progression. However, these authors do not demonstrate the reverse correlation between circulating angiogenin levels and survival, and they do not elucidate the source of angiogenin in the colorectal samples. In our clinical study, the issue of whether the angiogenin was produced in the breast carcinoma cells or in the surrounding stroma was not addressed. To establish the cellular source of angiogenin in breast cancer tissue, we performed additional immunohistochemical analysis.
Tissue sections were obtained from paraffin blocks of breast carcinomas in which cytosol angiogenin had been determined previously. In addition, samples of uninvolved breast were acquired. Incubation with a polyclonal anti-angiogenin antibody (R&D Systems) diluted at 1:20 in PBS (pH 7.4) was done on paraffin material. Sections were stained by avidin-biotin complex immunoperoxidase method and counterstained with hematoxilyn to visualize cell nuclei. The negative controls used were sections from the same tissue block in which the primary antibody was omitted. A cellular qualitative analysis of angiogenin staining was done. Sections were interpreted blinded to the previous angiogenin expression assays and to the clinical results.
In the breast carcinoma, the staining pattern for angiogenin was homogeneous and showed a strong cytoplasmic immunoreactivity located on the tumor cells (Fig. 1
, left). There were only a small number of weakly staining stromal cells such as fibroblasts, inflammatory cells, and capillary endothelial cells in the vicinity of the malignant cells. The epithelial localization of angiogenin was confirmed in normal breast specimens. Angiogenin immunodetection showed a staining pattern that was confined to the cytoplasm of the normal ductal epithelial cells (Fig. 1
, right).
|
FOOTNOTES
1 This work was supported by a fellowship from the Fundación Científica de la Asociación Española Contra el Cáncer (to S. M.) and by Grant FIS 96/0226 from the Fondo de Investigación Sanitaria, Spain. ![]()
2 To whom requests for reprints should be addressed, at Division of Medical Oncology, Hospital Universitario 12 de Octubre, Avda. de Córdoba Km 5.4, 28041 Madrid, Spain. E-mail: oncolab{at}h12o.es ![]()
3 To whom requests for reprints should be addressed, at Division of Medical Oncology, Hospital Universitario 12 de Octubre, Avda. de Córdoba Km 5.4, 28041 Madrid, Spain. E-mail: oncolab{at}h12o.es ![]()
Received 8/17/99; accepted 8/23/99.
REFERENCES
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |